InvestSMART

Raptor Metals Ltd (ASX: RAP) - Announcements

- Current share price for RAP : $0.026

ASX company news and announcements for Raptor Metals Ltd (RAP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Raptor Metals Ltd (RAP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Raptor Metals Ltd (RAP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Raptor Metals Ltd (RAP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$10 ResApp completes COVID-19 study recruitment in India 23 Nov 2021 9:56AM $0.055 $0.026 fallen by 52.73%
$10 Publication on challenges of diagnosing respiratory disease 19 Nov 2021 9:53AM $0.054 $0.026 fallen by 51.85%
$10 ResApp secures contract with global pharmaceutical company 18 Nov 2021 9:12AM $0.053 $0.026 fallen by 50.94%
$10 Partnership with Carepath for in-home COPD monitoring 16 Nov 2021 9:48AM $0.053 $0.026 fallen by 50.94%
$10 IRB approval for US COVID-19 study modification 15 Nov 2021 9:33AM $0.051 $0.026 fallen by 49.02%
$10 Jobkeeper Payments Notice 9 Nov 2021 7:10PM $0.049 $0.026 fallen by 46.94%
$10 Quarterly Activities Report and Appendix 4C 28 Oct 2021 8:46AM $0.063 $0.026 fallen by 58.73%
$10 Quarterly Results and Investor Conference Call Notification 27 Oct 2021 9:08AM $0.065 $0.026 fallen by 60%
$10 Notice of Annual General Meeting 26 Oct 2021 7:55PM $0.065 $0.026 fallen by 60%
$10 Presentations at Conferences 26 Oct 2021 9:35AM $0.064 $0.026 fallen by 59.38%
$10 COVID-19 Clinical Studies Update 26 Oct 2021 9:20AM $0.064 $0.026 fallen by 59.38%
$10 Notice under ASX Listing Rule 3.13.1 12 Oct 2021 5:29PM $0.068 $0.026 fallen by 61.76%
$10 ResApp announces FDA 510(k) submission for SleepCheckRx 11 Oct 2021 9:19AM $0.068 $0.026 fallen by 61.76%
$10 Notification regarding unquoted securities - RAP 1 Oct 2021 5:44PM $0.067 $0.026 fallen by 61.19%
$10 Notification of cessation of securities - RAP 1 Oct 2021 5:36PM $0.067 $0.026 fallen by 61.19%
$10 Change of Share Registry 1 Oct 2021 8:44AM $0.067 $0.026 fallen by 61.19%
$10 First patients recruited in COVID-19 clinical study in India 20 Sep 2021 8:30AM $0.081 $0.026 fallen by 67.90%
$10 ResApp receives Advanced and Overseas R&D Finding 14 Sep 2021 8:30AM $0.089 $0.026 fallen by 70.79%
$10 ResAppDx receives regulatory approval in Indonesia 1 Sep 2021 8:35AM $0.045 $0.026 fallen by 42.22%
$10 Appendix 4G 27 Aug 2021 9:43AM $0.048 $0.026 fallen by 45.83%
$10 Corporate Governance Statement 27 Aug 2021 9:37AM $0.048 $0.026 fallen by 45.83%
$10 Appendix 4E and Annual Report 27 Aug 2021 9:28AM $0.048 $0.026 fallen by 45.83%
$10 Investor Webinar Presentation 18 Aug 2021 8:54AM $0.043 $0.026 fallen by 39.53%
$10 ResApp expands COVID-19 clinical program 9 Aug 2021 8:44AM $0.047 $0.026 fallen by 44.68%
$10 Alodokter to launch ResAppDx in Indonesia 4 Aug 2021 9:56AM $0.040 $0.026 fallen by 35%

126 - 150 of 570 results

Page 6 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.